Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine added to escitalopram for obsessive-compulsive disorder
IRCT20211118053093N5Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Escitalopram + memantine with Escitalopram + placebo (2 arms). Primary endpoints: Yale-Brown Obsessive Compulsive Scale score and Barkley Deficits in Executive Functioning Scale score. Started Jul 2023; status: completed.
02
Drugs
memantineescitalopram
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20211118053093N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211118053093N5.